Abstract
In July 2007, all peritoneal dialysis (PD) patients in our hospital were switched from mupirocin to gentamicin ointment for daily application to the PD catheter exit site (CES). Our objective was to compare the efficacy of gentamicin and mupirocin in the prevention of catheter-related PD infections. We conducted an observational sequential cohort study to compare infectious outcomes with the 2 ointments. Mupirocin patients were followed retrospectively from January 2004 to June 2006 and gentamicin patients prospectively from July 2007 to December 2008. All patients were followed for 18 months following catheter insertion. Fifty-nine patients were included in the mupirocin arm and 37 patients in the gentamicin arm. Time to first infection (either CES or peritonitis) was similar between arms, with a probability of being infection-free at 12 months of 67% versus 53%, respectively (p=0.34). There were no differences in rates of overall infection (0.54 vs 0.56 infections per patient-year, respectively (p=0.94)) or peritonitis (0.41 vs 0.37 per patient-year, respectively (p=0.84). There were 5 pseudomonal infections in the mupirocin arm and none with gentamicin. It was concluded that topical gentamicin has comparable effectiveness to mupirocin for prevention of PD catheter-related infections.
Keywords: Gentamicin, mupirocin, peritoneal dialysis, peritonitis.
Current Drug Therapy
Title:Comparison of Gentamicin Ointment to Mupirocin Ointment for Prevention of Peritoneal Dialysis Catheter-Related Infections
Volume: 8 Issue: 1
Author(s): Katherine Wu, Erica Greanya, Karen Shalansky, Nadia Zalunardo, Guiyun Li and Suneet Singh
Affiliation:
Keywords: Gentamicin, mupirocin, peritoneal dialysis, peritonitis.
Abstract: In July 2007, all peritoneal dialysis (PD) patients in our hospital were switched from mupirocin to gentamicin ointment for daily application to the PD catheter exit site (CES). Our objective was to compare the efficacy of gentamicin and mupirocin in the prevention of catheter-related PD infections. We conducted an observational sequential cohort study to compare infectious outcomes with the 2 ointments. Mupirocin patients were followed retrospectively from January 2004 to June 2006 and gentamicin patients prospectively from July 2007 to December 2008. All patients were followed for 18 months following catheter insertion. Fifty-nine patients were included in the mupirocin arm and 37 patients in the gentamicin arm. Time to first infection (either CES or peritonitis) was similar between arms, with a probability of being infection-free at 12 months of 67% versus 53%, respectively (p=0.34). There were no differences in rates of overall infection (0.54 vs 0.56 infections per patient-year, respectively (p=0.94)) or peritonitis (0.41 vs 0.37 per patient-year, respectively (p=0.84). There were 5 pseudomonal infections in the mupirocin arm and none with gentamicin. It was concluded that topical gentamicin has comparable effectiveness to mupirocin for prevention of PD catheter-related infections.
Export Options
About this article
Cite this article as:
Wu Katherine, Greanya Erica, Shalansky Karen, Zalunardo Nadia, Li Guiyun and Singh Suneet, Comparison of Gentamicin Ointment to Mupirocin Ointment for Prevention of Peritoneal Dialysis Catheter-Related Infections, Current Drug Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574885511308010005
DOI https://dx.doi.org/10.2174/1574885511308010005 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial: Preeclampsia-Eclampsia, Time to Act and Time to Deepen Research
Current Women`s Health Reviews Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine β-Synthase (CBS) Genes as Risk Factors for Thrombophilias
Mini-Reviews in Medicinal Chemistry Meet Our Editor:
Current Clinical Pharmacology Current Trends in Using Internet and Mobile Technology to Support the Treatment of Substance Use Disorders
Current Drug Abuse Reviews Regulatory Mechanism of the Gastric Hyperemic Response Following Barrier Disruption: Roles of Cyclooxygenase-1, the Prostaglandin E<sub>2</sub>/EP1 Receptor and Sensory Neurons
Current Pharmaceutical Design High Resolution M-mode Evaluation of Jugular Vein Valves in Patients with Neurological and Neurosensory Disorders
Current Neurovascular Research Metabolic Syndrome During Menopause
Current Vascular Pharmacology Disorders of Respiration and Sleep-Disordered Breathing in Patients with Chronic Renal Failure
Current Respiratory Medicine Reviews Metalloproteinase-Mediated Shedding of Heparin-Binding Egf-Like Growth Factor and Its Pathophysiological Roles
Protein & Peptide Letters Effects of Diabetes on Murine Lipoproteins and Vascular Disease
Current Drug Targets Dose Related Patterns of Ventricular Arrhythmia due to Carvedilol Withdrawal in Patients with Systolic Heart Failure
Current Drug Safety Antioxidative Actions of Carvedilol in the Treatment of Hypertension
Current Cardiology Reviews Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Open Questions about Pulmonary Hypertension and Exercise Training: A Critical Review
Current Respiratory Medicine Reviews Leptin: A Promising Therapeutic Target with Pleiotropic Action Besides Body Weight Regulation
Current Drug Targets Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem
Current Cardiology Reviews Renin Inhibition as a New Strategy to Combat Cardiovascular Disease
Current Hypertension Reviews